PHIO Insider Trading (Phio Pharmaceuticals)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.52%

Insider Buying (Last 12 Months): $5,000.00

Insider Selling (Last 12 Months): $0.00

Phio Pharmaceuticals Insider Trading History Chart

Phio Pharmaceuticals Share Price & Price History

^$3.09

▼ -0.2 (-6.08%)

As of 02/25/2021 01:00 AM ET

Days: 30 | 90 | 365

This undiscovered CBD play is on the verge of disrupting the industry

From Emerging Markets Consulting | Ad

With recent health Canada approval they are poised to explode

Phio Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/19/2020	Gerrit Dispersyn	CEO	Buy	2,000	$2.50	$5,000.00

SEC Filings (Institutional Ownership Changes) for Phio Pharmaceuticals (NASDAQ:PHIO)

1.77% of Phio Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Phio Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/25/2021	Dimensional Fund Advisors LP	25,177	$68K	0.0%	N/A	0.178%
2/4/2021	GSA Capital Partners LLP	101,401	$0.27M	0.0%	+376.6%	1.754%
12/11/2020	Virtu Financial LLC	35,929	$77K	0.0%	N/A	0.622%
11/6/2020	GSA Capital Partners LLP	21,278	$46K	0.0%	N/A	0.368%
7/16/2020	Wedbush Securities Inc.	33,374	$73K	0.0%	N/A	0.577%
5/15/2020	Sabby Management LLC	255,194	$0.45M	0.2%	N/A	8.901%
5/12/2020	JPMorgan Chase & Co.	21,681	$38K	0.0%	N/A	0.755%
2/14/2020	UBS Group AG	45,409	$0.43M	0.0%	+43.3%	6.997%
2/13/2020	Renaissance Technologies LLC	333,890	$57K	0.0%	+585.9%	51.447%
1/28/2020	SG Americas Securities LLC	792,374	$0.14M	0.0%	+12.3%	121.904%
11/4/2019	SG Americas Securities LLC	705,353	$0.19M	0.0%	+16.9%	2.756%
8/16/2019	CVI Holdings LLC	406,358	$0.15M	0.1%	-32.8%	1.701%
8/14/2019	Citadel Advisors LLC	85,621	$33K	0.0%	+148.9%	0.358%
6/30/2019	SG Americas Securities LLC	603,528	$0.23M	0.0%	+163.8%	2.526%
4/29/2019	SG Americas Securities LLC	228,825	$0.10M	0.0%	+39.8%	1.026%
4/12/2019	Virtu Financial LLC	238,544	$0.11M	0.0%	N/A	1.070%

Data available starting January 2016

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum MÃ¼nchen. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Today's Range

Now: $3.09

$3.00

$3.37

50 Day Range

MA: $3.24

$2.81

$4.05

52 Week Range

Now: $3.09

$1.60

$6.48

Volume

923,899 shs

Average Volume

1,566,874 shs

Market Capitalization

$43.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.31

Who are the company insiders with the largest holdings of Phio Pharmaceuticals?

Phio Pharmaceuticals' top insider shareholders include:

Gerrit Dispersyn (CEO)

Who are the major institutional investors of Phio Pharmaceuticals?

Phio Pharmaceuticals' top institutional investors include:

GSA Capital Partners LLP — 1.75%
Dimensional Fund Advisors LP — 0.18%

Which institutional investors are buying Phio Pharmaceuticals stock?

During the previous quarter, PHIO stock was purchased by institutional investors including:

GSA Capital Partners LLP
Dimensional Fund Advisors LP